Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Medications and laboratory parameters as prognostic factors in amyotrophic lateral sclerosis.

Qureshi M, Shui A, Dibernardo AB, Brown RH Jr, Schoenfeld DA, Cudkowicz ME.

Amyotroph Lateral Scler. 2008 Dec;9(6):369-74. doi: 10.1080/17482960802163614. Review.

PMID:
18608098
2.

A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis.

Cudkowicz ME, Shefner JM, Schoenfeld DA, Brown RH Jr, Johnson H, Qureshi M, Jacobs M, Rothstein JD, Appel SH, Pascuzzi RM, Heiman-Patterson TD, Donofrio PD, David WS, Russell JA, Tandan R, Pioro EP, Felice KJ, Rosenfeld J, Mandler RN, Sachs GM, Bradley WG, Raynor EM, Baquis GD, Belsh JM, Novella S, Goldstein J, Hulihan J; Northeast ALS Consortium..

Neurology. 2003 Aug 26;61(4):456-64.

PMID:
12939417
3.

Functional outcome measures as clinical trial endpoints in ALS.

Traynor BJ, Zhang H, Shefner JM, Schoenfeld D, Cudkowicz ME; NEALS Consortium..

Neurology. 2004 Nov 23;63(10):1933-5.

PMID:
15557515
4.

The natural history of ALS is changing: improved survival.

Qureshi M, Schoenfeld DA, Paliwal Y, Shui A, Cudkowicz ME.

Amyotroph Lateral Scler. 2009 Oct-Dec;10(5-6):324-31. doi: 10.3109/17482960903009054.

PMID:
19922119
5.

[Revised amyotrophic lateral sclerosis functional rating scale at time of diagnosis predicts survival time in amyotrophic lateral sclerosis].

Liu XX, Fan DS, Zhang J, Zhang S, Zheng JY.

Zhonghua Yi Xue Za Zhi. 2009 Sep 22;89(35):2472-5. Chinese.

PMID:
20137433
6.

Creatine for amyotrophic lateral sclerosis/motor neuron disease.

Pastula DM, Moore DH, Bedlack RS.

Cochrane Database Syst Rev. 2010 Jun 16;(6):CD005225. doi: 10.1002/14651858.CD005225.pub2. Review. Update in: Cochrane Database Syst Rev. 2012;12:CD005225.

PMID:
20556761
7.

Creatine for amyotrophic lateral sclerosis/motor neuron disease.

Pastula DM, Moore DH, Bedlack RS.

Cochrane Database Syst Rev. 2012 Dec 12;12:CD005225. doi: 10.1002/14651858.CD005225.pub3. Review.

PMID:
23235621
8.
9.

Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).

Miller RG, Mitchell JD, Lyon M, Moore DH.

Amyotroph Lateral Scler Other Motor Neuron Disord. 2003 Sep;4(3):191-206. Review.

PMID:
13129806
11.

Linear estimates of disease progression predict survival in patients with amyotrophic lateral sclerosis.

Armon C, Graves MC, Moses D, Forté DK, Sepulveda L, Darby SM, Smith RA.

Muscle Nerve. 2000 Jun;23(6):874-82.

PMID:
10842262
12.

ALS clinical trials: do enrolled patients accurately represent the ALS population?

Chiò A, Canosa A, Gallo S, Cammarosano S, Moglia C, Fuda G, Calvo A, Mora G; PARALS group..

Neurology. 2011 Oct 11;77(15):1432-7. doi: 10.1212/WNL.0b013e318232ab9b.

PMID:
21956723
13.

Phosphorylated neurofilament heavy subunit (pNF-H) in peripheral blood and CSF as a potential prognostic biomarker in amyotrophic lateral sclerosis.

Boylan KB, Glass JD, Crook JE, Yang C, Thomas CS, Desaro P, Johnston A, Overstreet K, Kelly C, Polak M, Shaw G.

J Neurol Neurosurg Psychiatry. 2013 Apr;84(4):467-72. doi: 10.1136/jnnp-2012-303768.

PMID:
23117489
14.

Phase angle is a prognostic factor for survival in amyotrophic lateral sclerosis.

Desport JC, Marin B, Funalot B, Preux PM, Couratier P.

Amyotroph Lateral Scler. 2008 Oct;9(5):273-8. doi: 10.1080/17482960801925039.

PMID:
18720089
15.

The PRO-ACT database: design, initial analyses, and predictive features.

Atassi N, Berry J, Shui A, Zach N, Sherman A, Sinani E, Walker J, Katsovskiy I, Schoenfeld D, Cudkowicz M, Leitner M.

Neurology. 2014 Nov 4;83(19):1719-25. doi: 10.1212/WNL.0000000000000951.

16.

Can we eliminate placebo in ALS clinical trials?

Bryan WW, Hoagland RJ, Murphy J, Armon C, Barohn RJ, Goodpasture JC, Miller RG, Parry GJ, Petajan JH, Ross MA, Stromatt SC; rhCNTF ALS Study Group..

Amyotroph Lateral Scler Other Motor Neuron Disord. 2003 Apr;4(1):11-5.

PMID:
12745612
17.

Study of 962 patients indicates progressive muscular atrophy is a form of ALS.

Kim WK, Liu X, Sandner J, Pasmantier M, Andrews J, Rowland LP, Mitsumoto H.

Neurology. 2009 Nov 17;73(20):1686-92. doi: 10.1212/WNL.0b013e3181c1dea3.

18.
19.

The ALSFRSr predicts survival time in an ALS clinic population.

Kaufmann P, Levy G, Thompson JL, Delbene ML, Battista V, Gordon PH, Rowland LP, Levin B, Mitsumoto H.

Neurology. 2005 Jan 11;64(1):38-43.

PMID:
15642901
20.

A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis.

Pascuzzi RM, Shefner J, Chappell AS, Bjerke JS, Tamura R, Chaudhry V, Clawson L, Haas L, Rothstein JD.

Amyotroph Lateral Scler. 2010 May 3;11(3):266-71. doi: 10.3109/17482960903307805.

PMID:
19961264
Items per page

Supplemental Content

Support Center